Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria.

Huang DB, Strader CD, MacDonald JS, VanArendonk M, Peck R, Holland T.

Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003. doi: 10.1093/ofid/ofy003. eCollection 2018 Feb. Review.

2.

Mutagenesis approaches for elucidation of protein structure-function relationships.

Strader CD.

Curr Protoc Neurosci. 2001 May;Chapter 4:Unit 4.9. doi: 10.1002/0471142301.ns0409s03.

PMID:
18428492
3.

Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects.

Astrup A, Greenway FL, Ling W, Pedicone L, Lachowicz J, Strader CD, Kwan R; Ecopipam Obesity Study Group.

Obesity (Silver Spring). 2007 Jul;15(7):1717-31.

4.

Women making strides in big pharma.

Strader CD, Narula SK, Lachowicz JE.

Science. 2005 Sep 9;309(5741):1673. No abstract available.

PMID:
16150991
5.

Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor.

Shin N, Coates E, Murgolo NJ, Morse KL, Bayne M, Strader CD, Monsma FJ Jr.

Mol Pharmacol. 2002 Jul;62(1):38-47.

PMID:
12065753
6.

The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption.

Altmann SW, Davis HR Jr, Yao X, Laverty M, Compton DS, Zhu LJ, Crona JH, Caplen MA, Hoos LM, Tetzloff G, Priestley T, Burnett DA, Strader CD, Graziano MP.

Biochim Biophys Acta. 2002 Jan 30;1580(1):77-93.

PMID:
11923102
7.

Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788.

Lachowicz JE, Duffy RA, Ruperto V, Kozlowski J, Zhou G, Clader J, Billard W, Binch H 3rd, Crosby G, Cohen-Williams M, Strader CD, Coffin V.

Life Sci. 2001 Apr 27;68(22-23):2585-92.

PMID:
11392630
8.

Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.

Ok HO, Reigle LB, Candelore MR, Cascieri MA, Colwell LF, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang P, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Jul 17;10(14):1531-4.

PMID:
10915043
9.

Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.

Biftu T, Feng DD, Liang GB, Kuo H, Qian X, Naylor EM, Colandrea VJ, Candelore MR, Cascieri MA, Colwell LF Jr, Forrest MJ, Hom GJ, MacIntyre DE, Stearns RA, Strader CD, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Jul 3;10(13):1431-4.

PMID:
10888325
10.

Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.

Feng DD, Biftu T, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Jul 3;10(13):1427-9.

PMID:
10888324
11.

Molecular characterization of the melanin-concentrating hormone/receptor complex: identification of critical residues involved in binding and activation.

Macdonald D, Murgolo N, Zhang R, Durkin JP, Yao X, Strader CD, Graziano MP.

Mol Pharmacol. 2000 Jul;58(1):217-25.

PMID:
10860944
12.

Activation of the NPY Y5 receptor regulates both feeding and energy expenditure.

Hwa JJ, Witten MB, Williams P, Ghibaudi L, Gao J, Salisbury BG, Mullins D, Hamud F, Strader CD, Parker EM.

Am J Physiol. 1999 Nov;277(5):R1428-34. doi: 10.1152/ajpregu.1999.277.5.R1428.

PMID:
10564216
13.

Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore.

Mathvink RJ, Barritta AM, Candelore MR, Cascieri MA, Deng L, Tota L, Strader CD, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1869-74.

PMID:
10406657
14.

L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability.

Shih TL, Candelore MR, Cascieri MA, Chiu SH, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 May 3;9(9):1251-4.

PMID:
10340609
15.

Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides.

Naylor EM, Parmee ER, Colandrea VJ, Perkins L, Brockunier L, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang PR, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 Mar 8;9(5):755-8.

PMID:
10201842
16.

Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides.

Parmee ER, Naylor EM, Perkins L, Colandrea VJ, Ok HO, Candelore MR, Cascieri MA, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 Mar 8;9(5):749-54.

PMID:
10201841
17.

SCH 57790: a novel M2 receptor selective antagonist.

Lachowicz JE, Lowe D, Duffy RA, Ruperto V, Taylor LA, Guzik H, Brown J, Berger JG, Tice M, McQuade R, Kozlowski J, Clader J, Strader CD, Murgolo N.

Life Sci. 1999;64(6-7):535-9.

PMID:
10069520
18.

Presenilins interact with armadillo proteins including neural-specific plakophilin-related protein and beta-catenin.

Levesque G, Yu G, Nishimura M, Zhang DM, Levesque L, Yu H, Xu D, Liang Y, Rogaeva E, Ikeda M, Duthie M, Murgolo N, Wang L, VanderVere P, Bayne ML, Strader CD, Rommens JM, Fraser PE, St George-Hyslop P.

J Neurochem. 1999 Mar;72(3):999-1008.

19.

3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists.

Naylor EM, Colandrea VJ, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang PR, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1998 Nov 3;8(21):3087-92.

PMID:
9873681
20.

3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties.

Weber AE, Ok HO, Alvaro RF, Candelore MR, Cascieri MA, Chiu SH, Deng L, Forrest MJ, Hom GJ, Hutchins JE, Kao J, MacIntyre DE, Mathvink RJ, McLoughlin D, Miller RR, Newbold RC, Olah TV, Parmee ER, Perkins L, Stearns RA, Strader CD, Szumiloski J, Tang YS, Tota L, Fisher MH, et al.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2111-6.

PMID:
9873496
21.

Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist.

Parmee ER, Ok HO, Candelore MR, Tota L, Deng L, Strader CD, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1998 May 5;8(9):1107-12.

PMID:
9871717
22.

Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor.

Weber AE, Mathvink RJ, Perkins L, Hutchins JE, Candelore MR, Tota L, Strader CD, Wyvratt MJ, Fisher MH.

Bioorg Med Chem Lett. 1998 May 5;8(9):1101-6.

PMID:
9871716
23.

Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation.

Hwa JJ, Ghibaudi L, Williams P, Witten MB, Tedesco R, Strader CD.

Peptides. 1998;19(5):869-75.

PMID:
9663452
24.

A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys.

Fisher MH, Amend AM, Bach TJ, Barker JM, Brady EJ, Candelore MR, Carroll D, Cascieri MA, Chiu SH, Deng L, Forrest MJ, Hegarty-Friscino B, Guan XM, Hom GJ, Hutchins JE, Kelly LJ, Mathvink RJ, Metzger JM, Miller RR, Ok HO, Parmee ER, Saperstein R, Strader CD, Stearns RA, MacIntyre DE, et al.

J Clin Invest. 1998 Jun 1;101(11):2387-93.

25.

Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats.

Davis HR Jr, Mullins DE, Pines JM, Hoos LM, France CF, Compton DS, Graziano MP, Sybertz EJ, Strader CD, Van Heek M.

Obes Res. 1998 Mar;6(2):147-56.

26.

Molecular approaches to the discovery of new treatments for obesity.

Strader CD, MacIntyre DE, Candelore MR, Parker EM.

Curr Opin Chem Biol. 1997 Aug;1(2):204-9. Review.

PMID:
9667852
27.

Genomic organization and functional characterization of the mouse GalR1 galanin receptor.

Wang S, He C, Maguire MT, Clemmons AL, Burrier RE, Guzzi MF, Strader CD, Parker EM, Bayne ML.

FEBS Lett. 1997 Jul 14;411(2-3):225-30.

28.

Expression of B1 and B2 bradykinin receptor mRNA and their functional roles in sympathetic ganglia and sensory dorsal root ganglia neurones from wild-type and B2 receptor knockout mice.

Seabrook GR, Bowery BJ, Heavens R, Brown N, Ford H, Sirinathsinghi DJ, Borkowski JA, Hess JF, Strader CD, Hill RG.

Neuropharmacology. 1997 Jul;36(7):1009-17.

PMID:
9257945
29.

Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.

Cascieri MA, Ber E, Fong TM, Hale JJ, Tang F, Shiao LL, Mills SG, MacCoss M, Sadowski S, Tota MR, Strader CD.

Eur J Pharmacol. 1997 May 1;325(2-3):253-61.

PMID:
9163573
30.

Leptin increases energy expenditure and selectively promotes fat metabolism in ob/ob mice.

Hwa JJ, Fawzi AB, Graziano MP, Ghibaudi L, Williams P, Van Heek M, Davis H, Rudinski M, Sybertz E, Strader CD.

Am J Physiol. 1997 Apr;272(4 Pt 2):R1204-9.

PMID:
9140021
31.

Diet-induced obese mice develop peripheral, but not central, resistance to leptin.

Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR Jr.

J Clin Invest. 1997 Feb 1;99(3):385-90.

32.

Intracerebroventricular injection of leptin increases thermogenesis and mobilizes fat metabolism in ob/ob mice.

Hwa JJ, Ghibaudi L, Compton D, Fawzi AB, Strader CD.

Horm Metab Res. 1996 Dec;28(12):659-63.

PMID:
9013737
33.

The relationship of tissue localization, distribution and turnover to feeding after intraperitoneal 125I-leptin administration to ob/ob and db/db mice.

Van Heek M, Mullins DE, Wirth MA, Graziano MP, Fawzi AB, Compton DS, France CF, Hoos LM, Casale RL, Sybertz EJ, Strader CD, Davis HR Jr.

Horm Metab Res. 1996 Dec;28(12):653-8.

PMID:
9013736
34.

Presenilin mutations in Alzheimer's disease: molecular models suggest a potential functional locus.

Murgolo NJ, Brown JE, Bayne ML, Strader CD.

Trends Pharmacol Sci. 1996 Nov;17(11):389-93. Review. No abstract available. Erratum in: Trends Pharmacol Sci 1996 Dec;17(12):465.

PMID:
8990952
35.

Cloning and expression of a novel neuropeptide Y receptor.

Weinberg DH, Sirinathsinghji DJ, Tan CP, Shiao LL, Morin N, Rigby MR, Heavens RH, Rapoport DR, Bayne ML, Cascieri MA, Strader CD, Linemeyer DL, MacNeil DJ.

J Biol Chem. 1996 Jul 12;271(28):16435-8.

36.

Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic.

Hirschmann R, Yao W, Cascieri MA, Strader CD, Maechler L, Cichy-Knight MA, Hynes J Jr, van Rijn RD, Sprengeler PA, Smith AB 3rd.

J Med Chem. 1996 Jun 21;39(13):2441-8.

PMID:
8691440
37.

Nociception and inflammatory hyperalgesia in B2 bradykinin receptor knockout mice.

Boyce S, Rupniak NM, Carlson EJ, Webb J, Borkowski JA, Hess JF, Strader CD, Hill RG.

Immunopharmacology. 1996 Jun;33(1-3):333-5. No abstract available.

PMID:
8856178
38.

Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant.

Candelore MR, Deng L, Tota LM, Kelly LJ, Cascieri MA, Strader CD.

Endocrinology. 1996 Jun;137(6):2638-41.

PMID:
8641219
39.

Purification and reconstitution of a recombinant human neurokinin-1 receptor.

Mazina KE, Strader CD, Tota MR, Daniel S, Fong TM.

J Recept Signal Transduct Res. 1996 May-Jul;16(3-4):191-207.

PMID:
8897311
40.

2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist.

Hale JJ, Mills SG, MacCoss M, Shah SK, Qi H, Mathre DJ, Cascieri MA, Sadowski S, Strader CD, MacIntyre DE, Metzger JM.

J Med Chem. 1996 Apr 26;39(9):1760-2. No abstract available.

PMID:
8627597
41.

Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice.

Zhang B, Graziano MP, Doebber TW, Leibowitz MD, White-Carrington S, Szalkowski DM, Hey PJ, Wu M, Cullinan CA, Bailey P, Lollmann B, Frederich R, Flier JS, Strader CD, Smith RG.

J Biol Chem. 1996 Apr 19;271(16):9455-9.

42.

The view from inside the receptor.

Strader CD.

J Med Chem. 1996 Jan 5;39(1):1. No abstract available.

PMID:
8568795
43.
44.

Conformational compatibility as a basis of differential affinities of tachykinins for the neurokinin-1 receptor.

Huang RR, Huang D, Strader CD, Fong TM.

Biochemistry. 1995 Dec 19;34(50):16467-72.

PMID:
8845375
45.

Interaction of [fluorescein-Trp25]glucagon with the human glucagon receptor expressed in Drosophila Schneider 2 cells.

Tota MR, Xu L, Sirotina A, Strader CD, Graziano MP.

J Biol Chem. 1995 Nov 3;270(44):26466-72.

46.

Isolation of a preadipocyte cell line from rat bone marrow and differentiation to adipocytes.

Marko O, Cascieri MA, Ayad N, Strader CD, Candelore MR.

Endocrinology. 1995 Oct;136(10):4582-8.

PMID:
7545105
47.
48.

Identification of residues involved in ligand binding to the neurokinin-2 receptor.

Huang RR, Vicario PP, Strader CD, Fong TM.

Biochemistry. 1995 Aug 8;34(31):10048-55.

PMID:
7543277
49.

Molecular characterization of a common binding site for small molecules within the transmembrane domain of G-protein coupled receptors.

Cascieri MA, Fong TM, Strader CD.

J Pharmacol Toxicol Methods. 1995 Aug;33(4):179-85. Review.

PMID:
8527825
50.

Mutational analysis of neurokinin receptor function.

Fong TM, Huang RC, Yu H, Swain CJ, Underwood D, Cascieri MA, Strader CD.

Can J Physiol Pharmacol. 1995 Jul;73(7):860-5. Review.

PMID:
8846422

Supplemental Content

Loading ...
Support Center